Sign In
Buy ARGX
$876.25
-1.37 (-0.156%)
At Close: Jul 13, 2026
Are Medical Stocks Lagging Argenx (ARGX) This Year?
10:40am, Monday, 13'th Jul 2026
Here is how argenex SE (ARGX) and Cardinal Health (CAH) have performed compared to their sector so far this year.
FTRE or ARGX: Which Is the Better Value Stock Right Now?
12:41pm, Tuesday, 07'th Jul 2026
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Fortrea Holdings Inc. (FTRE) and argenex SE (ARGX). But which of these two stocks offers
This Profitable Autoimmune Biotech Trades Near A High And A Buy Point
01:10pm, Monday, 06'th Jul 2026
This profitable Netherlands-based biotech name has produced triple-digit quarterly earnings growth.
Live Nasdaq Composite: Markets Kick Off H2 2026 on Cautious Note amid Chip Stock Profit Taking
09:42am, Wednesday, 01'st Jul 2026
Live Updates Don't wait: the analyst who called NVIDIA in 2010 just revealed his top 10 AI stocks. See the full list FREE now. Wells Fargo's Q3 Outlook 51 minutes ago Live Wells Fargo is betting on a
Argenx Analyst Is Bullish Despite Changes To Phase 3 Myositis Study
01:57pm, Thursday, 25'th Jun 2026
Argenx SE (NASDAQ:ARGX) stock has faced pressure after the company disclosed changes to the analysis plan for its ongoing Phase 3 Vyvgart study in myositis.
Can Argenx Retake Its Record High — And A Buy Point — On A New Vyvgart Strategy?
10:29am, Wednesday, 24'th Jun 2026
Argenx stock reversed course Wednesday, bumping above its 21-day line, as investors digested its myositis-focused R&D Day.
argenx SE (ARGX) Discusses R&D Spotlight on Advancing FcRn Leadership in Autoimmune Myositis Transcript
01:32am, Wednesday, 24'th Jun 2026
argenx SE (ARGX) Discusses R&D Spotlight on Advancing FcRn Leadership in Autoimmune Myositis Transcript
argenx Eyes More VYVGART Growth as Pipeline Catalysts Near
07:07am, Friday, 12'th Jun 2026
Executives at argenex NASDAQ: ARGX told investors at a Goldman Sachs healthcare event that they continue to see meaningful growth opportunities for VYVGART across myasthenia gravis and chronic inflamm
Sanofi, An Argenx Rival, Bites The Dust — But A Third Biotech Took The Biggest Hit
10:15am, Wednesday, 10'th Jun 2026
Sanofi scrapped a final-phase study Wednesday of an experimental CIDP treatment. The stock tumbled in response.
ARGX Shares Gain Nearly 9% in a Month: Here's What You Need to Know
09:11am, Wednesday, 10'th Jun 2026
argenx stock rises nearly 9% in a month after the FDA expands Vyvgart's gMG label, opening treatment to adult patients regardless of antibody status.
argenx SE (ARGX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
01:22am, Wednesday, 10'th Jun 2026
argenx SE (ARGX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
SRPT vs. ARGX: Which Stock Is the Better Value Option?
12:41pm, Monday, 08'th Jun 2026
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Sarepta Therapeutics (SRPT) or argenex SE (ARGX). But which of these two companies is the bes
Argenx (ARGX) Soars 5.8%: Is Further Upside Left in the Stock?
10:01am, Monday, 08'th Jun 2026
Argenx (ARGX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength dow
argenx Touts VYVGART Growth, 50,000-Patient Goal at William Blair Conference
06:03am, Friday, 05'th Jun 2026
argenx NASDAQ: ARGX Chief Financial Officer Karl Gubitz told investors at the 46th Annual William Blair Growth Stock Conference that the biotechnology company remains focused on revenue growth, profit
argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026
01:00am, Wednesday, 03'rd Jun 2026
ALKIVIA+ data in myositis indicate efgartigimod provides sustained, clinically meaningful improvements and consistent safety RHO+ data in Sjogren's disease indicate maintenance of response following s
